Movement Alert｜Giant Biogene Falls 5.18% in Regular Trading, Profit-Taking After Prior Session Surge Amid Consumer Sector Valuation Pressure

Market Focus06-25

On June 25, Giant Biogene fell 5.18% in regular trading, trading at approximately HK$24.9 per share, with turnover of HK$33.48 million. The decline followed a 5.45% surge in the prior session triggered by regulatory approval of the company's crosslinked recombinant collagen implant.

On the news front, CICC maintained its Outperform rating on Giant Biogene but cut the target price by 18% to HK$40, citing broad valuation compression across the Hong Kong consumer sector. The current share price corresponds to forward P/E ratios of 12x and 11x for projected earnings in the coming two years. The approved product is the world's first crosslinked recombinant Type III full-length collagen filler indicated for neck wrinkles, with differentiated positioning. However, today's session saw clear profit-taking pressure following yesterday's rally.

Within the Personal Products sector, the broader industry traded lower. Among individual stocks, Butong Group fell 8.45%, MAO GEPING fell 3.98%, CHICMAX fell 3.06%, SOFTCARE fell 2.15%, while Hengan International edged up 0.18%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1164694526?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 10:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164694526","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Giant Biogene Falls 5.18% in Regular Trading, Profit-Taking After Prior Session Surge Amid Consumer Sector Valuation Pressure","media":"Market Focus","content":"<p><p>On June 25, Giant Biogene fell 5.18% in regular trading, trading at approximately HK$24.9 per share, with turnover of HK$33.48 million. The decline followed a 5.45% surge in the prior session triggered by regulatory approval of the company's crosslinked recombinant collagen implant.</p><p>On the news front, CICC maintained its Outperform rating on Giant Biogene but cut the target price by 18% to HK$40, citing broad valuation compression across the Hong Kong consumer sector. The current share price corresponds to forward P/E ratios of 12x and 11x for projected earnings in the coming two years. The approved product is the world's first crosslinked recombinant Type III full-length collagen filler indicated for neck wrinkles, with differentiated positioning. However, today's session saw clear profit-taking pressure following yesterday's rally.</p><p>Within the Personal Products sector, the broader industry traded lower. Among individual stocks, Butong Group fell 8.45%, MAO GEPING fell 3.98%, CHICMAX fell 3.06%, SOFTCARE fell 2.15%, while Hengan International edged up 0.18%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Giant Biogene Falls 5.18% in Regular Trading, Profit-Taking After Prior Session Surge Amid Consumer Sector Valuation Pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Giant Biogene Falls 5.18% in Regular Trading, Profit-Taking After Prior Session Surge Amid Consumer Sector Valuation Pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-25 10:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 25, Giant Biogene fell 5.18% in regular trading, trading at approximately HK$24.9 per share, with turnover of HK$33.48 million. The decline followed a 5.45% surge in the prior session triggered by regulatory approval of the company's crosslinked recombinant collagen implant.</p><p>On the news front, CICC maintained its Outperform rating on Giant Biogene but cut the target price by 18% to HK$40, citing broad valuation compression across the Hong Kong consumer sector. The current share price corresponds to forward P/E ratios of 12x and 11x for projected earnings in the coming two years. The approved product is the world's first crosslinked recombinant Type III full-length collagen filler indicated for neck wrinkles, with differentiated positioning. However, today's session saw clear profit-taking pressure following yesterday's rally.</p><p>Within the Personal Products sector, the broader industry traded lower. Among individual stocks, Butong Group fell 8.45%, MAO GEPING fell 3.98%, CHICMAX fell 3.06%, SOFTCARE fell 2.15%, while Hengan International edged up 0.18%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02367","symbol_name":"巨子生物","start_time":0,"source_url":"","article_id":"1164694526","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164694526","pubTimestamp":1782353708,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 25, Giant Biogene fell 5.18% in regular trading, trading at approximately HK$24.9 per share, with turnover of HK$33.48 million. The decline followed a 5.45% surge in the prior session...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02367":"巨子生物"},"translate_title":"动向提示|巨头Biogene常规交易下跌5.18%，消费板块估值承压下前一交易日大涨后获利了结","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02367":1},"content_text":"On June 25, Giant Biogene fell 5.18% in regular trading, trading at approximately HK$24.9 per share, with turnover of HK$33.48 million. The decline followed a 5.45% surge in the prior session triggered by regulatory approval of the company's crosslinked recombinant collagen implant.On the news front, CICC maintained its Outperform rating on Giant Biogene but cut the target price by 18% to HK$40, citing broad valuation compression across the Hong Kong consumer sector. The current share price corresponds to forward P/E ratios of 12x and 11x for projected earnings in the coming two years. The approved product is the world's first crosslinked recombinant Type III full-length collagen filler indicated for neck wrinkles, with differentiated positioning. However, today's session saw clear profit-taking pressure following yesterday's rally.Within the Personal Products sector, the broader industry traded lower. Among individual stocks, Butong Group fell 8.45%, MAO GEPING fell 3.98%, CHICMAX fell 3.06%, SOFTCARE fell 2.15%, while Hengan International edged up 0.18%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1164694526","isCrawlerRequest":true}